Company Description
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients.
It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body.
It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody.
The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025.
INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
| Country | United States |
| Founded | 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Steven Shum |
Contact Details
Address: 5582 Broadcast Court Sarasota, Florida 34240 United States | |
| Phone | 978-878-9505 |
| Website | invobioscience.com |
Stock Details
| Ticker Symbol | IVF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001417926 |
| CUSIP Number | 44984F708 |
| ISIN Number | US44984F7087 |
| Employer ID | 20-4036208 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Shum | Chief Executive Officer and Director |
| Dr. Daniel Gedeon Teper MBA, PharmD | President and Director |
| Andrea Goren | Chief Financial Officer |
| Lyn Falconio | Chief Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 1, 2025 | 8-K | Current Report |
| Jul 23, 2025 | 8-K | Current Report |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 6, 2025 | 8-K | Current Report |
| Jun 4, 2025 | DEF 14A | Other definitive proxy statements |